Colchicine

Generic Name: Colchicine

Brand Names: Colcrys, Gloperba, Lodoco, Mitigare

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₅NO_₆

CAS Number: 64-86-8

Unique Ingredient Identifier: SML2Y3J35T

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Background: Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has also been investigated in other inflammatory and fibrotic conditions.

Indication: Colchicine is indicated for the prophylaxis and treatment of gout flares. It is also indicated in Familial Mediterranean fever (FMF) in children and adults of four years of age and older. It is also indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.

Some off-label uses of colchicine include the treatment of the manifestations of Behcet's syndrome, pericarditis, and postpericardiotomy syndrome.

Associated Conditions: Behcet's Syndrome, Cardiovascular Mortality, Coronary Revascularization, Familial Mediterranean Fever (FMF ), Gout Flares, Myocardial Infarction, Pericarditis, Postpericardiotomy Syndrome, Stroke

Clinical Trials

Colchicine Use in Intracranial Atherosclerotic Disease

Phase 2

Recruiting

Conditions: ICAD - Intracranial Atherosclerotic Disease

Interventions: Drug: Colchicine 0.5 MG

First Posted Date: 2022-08-16

Last Posted Date: 2023-02-13

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 72

Registration Number: NCT05503225

Locations: 🇭🇰
Chinese University of Hong Kong, Hong Kong, Hong Kong

Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis

Phase 3

Recruiting

Conditions: Stroke, Ischemic
Atherosclerosis
Myocardial Infarction
Cerebral Infarction
Stroke
Coronary Syndrome
TIA
Cardiac Disease

Interventions: Drug: Colchicine 0.5 MG
Drug: Aspirin 75-300mg
Drug: Ticagrelor 90mg

First Posted Date: 2022-07-27

Last Posted Date: 2024-06-03

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 2800

Registration Number: NCT05476991

Locations: 🇫🇷
URC Lariboisière-Fernand Widal-Saint Louis, Paris, France

Effect of Colchicine on Coronary Reperfusion in Patients With Acute Coronary Syndrome

Phase 2

Recruiting

Conditions: Acute Coronary Syndrome

Interventions: Drug: Colchicine

First Posted Date: 2022-07-25

Last Posted Date: 2023-11-18

Lead Sponsor: Pontificia Universidad Catolica de Chile

Target Recruit Count: 50

Registration Number: NCT05472337

Locations: 🇨🇱
Hospital Clínico Pontificia Universidad Catolica de Chile, Santiago, Chile

Use of Colchicine to Decrease Atrial Fibrillation Recurrence After Ablation

Phase 3

Recruiting

Conditions: Atrial Fibrillation

Interventions: Drug: Colchicine 0.6 mg
Drug: Placebo

First Posted Date: 2022-07-15

Last Posted Date: 2022-07-15

Lead Sponsor: Stony Brook University

Target Recruit Count: 224

Registration Number: NCT05459974

Locations: 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States

Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)

Phase 3

Completed

Conditions: Ischemic Stroke
TIA

Interventions: Drug: Placebo colchicine
Drug: Colchicine

First Posted Date: 2022-06-30

Last Posted Date: 2024-06-25

Lead Sponsor: Beijing Tiantan Hospital

Target Recruit Count: 8343

Registration Number: NCT05439356

Locations: 🇨🇳
Baoding Xushui District People's Hospital, Baoding, Hebei, China
🇨🇳
Hebei Tang County People Hospital, Baoding, Hebei, China
🇨🇳
People's Hospital of Zhongwei, Zhongwei, Ningxia, China

and more 241 locations